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Abstract
Introduction: The pathophysiology of pulmonary embolism (PE) represents complex, multifactorial processes involving blood
cells, vascular endothelium, and the activation of inﬂammatory pathways. Platelet (P), endothelial (E), and leukocyte (L)-selectin
molecules may play an important role in PE pathophysiology. We aimed to proﬁle the biomarkers of inﬂammation, including
selectins in PE patients, and compare them to healthy individuals.
Materials and methods: 100 acute PE patients and 50 controls were included in this case control study. ELISA methods were
used to quantify levels of selectins, inﬂammatory, and hemostatic biomarkers.
Results: In PE patients, levels of selectin molecules as compared to controls convey increased P-selectin levels (95 ng/mL vs 40 ng/
mL, p < .0001) and decreased L-selectin levels (1468 ng/mL vs 1934 ng/mL, p < .0001). Signiﬁcant correlations were found between
selectins and Plasminogen Activating Inhibitor-1 (PAI-1), Tumor Necrosis Factor-a (TNFa), and D-dimer. Fold change between selectins and controls is compared to other biomarkers, illustrating degrees of change comparable to TNFa, alpha-2-antiplasmin, and
microparticles. L-selectin levels are inversely associated with all-cause-mortality in PE patients, (p = .040).
Conclusion: These studies suggest that various thrombo-inﬂammatory biomarkers are elevated in PE patients. Furthermore, Lselectin levels are inversely associated with mortality outcomes.
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Introduction
Pulmonary embolism (PE) is a common disease complication in
the hospital setting and one of the most frequent causes of
death.1,2 Among the many risk factors for PE development
are history of cancer, surgery, and inﬂammation.2–4 Females
who are pregnant or are taking oral contraceptives also have a
higher chance of developing PE.4 PE has been found to be
more prevalent in elderly populations, overweight individuals,
as well as individuals who smoke tobacco.5 Clinical presentation of PE often includes hemoptysis, severe chest pain,
dyspnea, and syncope.5 Many diagnostic tools have been extensively studied and adopted, including the Wells Criteria,
D-dimer, V/Q scan, and CT angiography.2,5,6 These laboratory
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and conﬁrmatory tests have made the diagnosis of PE more
approachable in the clinical setting.
While diagnosis of PE has become routine clinical practice,
risk stratiﬁcation of the condition has been more challenging.
Prediction of clinical outcomes of PE is a growing area of
research, which is now exploring the role of biomarkers.
Right ventricular dysfunction as well as troponin levels were
studied by Becattini et.al. and used to create a predictive
model for mortality outcomes in PE patients.7 Jovanovic et.al.
examined the biomarker Brain Natriuretic peptide (BNP) and
was able to illustrate a statistically signiﬁcant correlation
between BNP and PE mortality 30 days from onset of the diagnosis.8 Other studies, such as those by Surov et.al., sought out
to create a predictive model for PE mortality using parameters
such as troponin, pH, blood pressure, age and gender.9
Inﬂammatory and hemostatic activation biomarkers such as
Alpha-2-antiplasmin, C-reactive Protein, D-dimer, MMP-9,
microparticles, and TNFa have been extensively studied in
venous thromboembolic conditions.1,3 Despite these studies
about the predictive value and correlations of various parameters to mortality outcomes, adhesion molecules, such as P, E,
and L-selectins, have not been examined for their clinical use
in prediction of outcomes.
P-selectin is a cell adhesion molecule which is located on the
outer membrane of endothelial cells and platelets.10 P-selectin
interacts with other cellular components through attachment
to its ligand, PSGL-1, which is located on leukocytes. This
interaction permits for the cross linkages of white cell molecules, which is of substantial importance to thrombus development. P-selectin has been found to increase tissue factor levels
in other white cells, further contributing to the creation of a new
thrombus.11,12 Increased levels of P-selectin have been reported
in many thrombotic conditions, including ischemic stroke and
myocardial infarction.13 Research studies have conveyed that
a substantial increase in P-selectin levels in plasma is evident
within just hours of the initial development of the thrombus.14
Studies by Mosevell et.al. have demonstrated signiﬁcantly elevated levels of P-selectin in PE patients and have even suggested its use as a screening biomarker.14 The speciﬁcity of
P-selectin for diagnosis of PE was greater than 97% in one
study.14 Metanalysis by Antonopoulos et.al. reinforced that
there was an elevation of soluble P-selectin levels in patients
with a prior deep venous thrombosis.13 Xie et.al. examined
P-selectin at the mRNA level in PE patients, also demonstrating
an elevated quantity of the biomarker within the experimental
cohort.4 Additional studies of the relationship of P-selectin to
other biomarkers of inﬂammation and hemostasis is necessary
in order to more completely understand its role.
E-selectin is an adhesion molecule that is unique in that it is
only found on the endothelium. Under normal conditions,
E-selectin expression is limited to microvessels, but this can
be ampliﬁed in pathologic, inﬂammatory, states.15 Many
studies have conveyed that one of the primary functions of
E-selectin is to permit rolling or migration of leukocytes
along the endothelium in pathologic states.16 In fact, recent
studies have conveyed that this function is not limited to
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E-selectin, but rather all three selectins can partake in this
role. In-vivo studies have illustrated that L-selectins have the
fastest rolling speed, followed by P then E-selectin.17 Past
studies have conveyed that E-selectin levels become more upregulated in inﬂammatory states, speciﬁcally citing molecules
such as TNFa. It has also been suggested that a co-expression
of P and E-selectin molecules takes place in inﬂammatory
states, illustrating a co-dependent relationship between the
two.17 Further support for this codependency among P and E
-selectin are reported in mice models which showed much
smaller thrombi in the absence of both P and E-selectin
versus in the absence of only P-selectin or E-selectin.15
However, despite this initial upregulation, studies have conveyed a substantial decline in levels of E-selectin, likely due
to its breakdown in lysosomes shortly after translation.17
Further supporting this concept, Xie et.al. reported a lower
level of E-selectin mRNA in PE patients, speciﬁcally.4
L-selectin is an adhesion molecule that is located on the
outside surface of leukocyte molecules.18 More speciﬁcally,
L-selectin has been found on T-cells, B-cells, neutrophils,
monocytes, and natural killer cells.17 This position allows for
leukocytes to translocate across and through the endothelium
to reach locations of injury or inﬂammation.18,19 This concept
has been proven through knock-out studies of L-selectin,
which have subsequently led to impaired rolling of leukocytes
in in-vivo studies.17 It has been reported that quantiﬁable
levels of L-selectin can be found in normal healthy individuals.17 Upregulation of L-selectin levels is associated with
inﬂammatory states; this concept has been illustrated by knockout L-selectin mice demonstrating lower levels of inﬂammation
than those who possess intact L-selectin.15 Xie et.al. studied
selectin molecules at the mRNA level, reporting higher levels
of L-selectin in PE patients. This, the researchers noted, suggested the abundant recruitment of white cells during the development of a PE.4
The current study aims to quantify levels of selectins in PE
patients and controls, correlate selectin levels to other biomarkers of hemostatic activation and inﬂammation, compare degree
of magniﬁcation of selectins in PE patients to degree of magniﬁcation of other hemostatic and inﬂammatory biomarkers, and
examine potential correlations of selectins to mortality outcomes. These studies will provide further elucidation of the
mechanistic role of selectin molecules in PE pathogenesis,
while allowing for investigation of another biomarker that can
be indicative of negative patient outcomes.

Materials and Methods
Patient Population
Patients 18 years old and over presenting to Loyola University
Medical Center (LUMC) with acute PE between March and
June 2019 were included in a prospective database for the PE
Response Team (PERT) Trial, and consenting patients underwent phlebotomy for research purposes following hospital
admission. The age ranged from 18 to 101 (Mean = 63 ± 16
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years). The gender of the group was equally balanced.
Diagnosis was made using CT angiography or ventilation perfusion (VQ) scan conﬁrmed by PERT team. A random selection of patients with varying PE severity (as deﬁned by the
European Society of Cardiology classiﬁcation system) were
selected for inclusion in this study using a random number
generator.20 The study was approved by the Institutional
Review Board.

Quantiﬁcation of Biomarker Levels
Blood was drawn from all patients within 72 hours after PE
diagnosis. All samples were de-identiﬁed. Plasma was isolated
via centrifugation of the sample, which was subsequently aliquoted and frozen until use. Control citrated plasma (N = 50)
of normal human volunteers, apparently free of any on board
medication, was purchased from the vendor George King
Biomedical, Inc., Overland Park, KS. This control cohort has
been used for the comparison of the biomarker levels in all
studies carried out in conjunction with the PERT program.
Commercially available Enzyme Linked Immunosorbent
Assays (ELISA) for Alpha-2-antiplasmin, C-reactive Protein,
D-dimer, MMP-9, microparticles, TNFa, and P, E, and
L-selectin are performed according to enclosed package procedures. Normal samples comprised of 50 plasma samples collected from healthy male and female individuals. An
additional mixed pool of plasma obtained from 50 healthy
male and 50 healthy female volunteers, referenced as Normal
Human Plasma (NHP), was also used for comparison purposes.

Table 1. Biomarkers of Hemostatic Dysregulation, Inﬂammatory
Process, and Selectins in Patients with PE and Their Comparison
with Normal Controls
Parameter

Mean ± SD
Median (SEM)

D-Dimer (ng/mL)

5032

MMP-9

216

CRP (ug/mL)
PAI-1 (ng/mL)
Microparticles (nM)
TNFa (pg/mL)
Alpha-2 Anti-Plasmin
(%)
P-Selectin (ng/mL)

E-Selectin (ng/mL)
L-Selectin (ng/mL)

Fold Change (PE/
NHP NHP)
202 34.6

13
60
59
64
83

6986 ± 5879
(446)
815 ± 4472
(397)
36 ± 51 (4)
69 ± 46 (3)
80 ± 64 (5)
98 ± 107 (12)
90 ± 41 (3)

77

60
1353

51

16

4
22
29
49
100

9
3.1
2.8
2
0.9

95 ± 65 (7)

46

2.1

65 ± 33 (3)
1468 ± 588
(59)

74 0.9
1806 0.8

All values represent mean ± 1 SD (SEM) of PE patients and their comparison
with normal controls. In addition, the median values are also provided for
comparison purposes. Fold changes in the biomarker levels is calculated in
reference to NHP.

Data Analysis
Mean, median, standard deviation, and standard error of the
mean were calculated for Alpha-2-antiplasmin, C-reactive
Protein, D-dimer, MMP-9, microparticles, TNFa, and P, E,
and L-selectin. Fold change of PE patients as compared to the
mixed pool of healthy male and female volunteers, referenced
in the paper as normal human plasma or NHP, was calculated
by dividing the mean of the biomarker in PE patients by the biomarker level in NHP. Biomarkers were then ranked by fold
change from greatest fold change to smallest fold change.
Two-tailed Wilcoxon Mann Whitney tests were used to
compare selectin levels in PE patients and 50 human controls.
Statistical tests with p = .05 were executed using Graphpad
Prism Software. Spearman correlational studies relating P, E,
and L-selectin, PAI-1, TNFa, and D-dimer were performed
using Graphpad Prism Software. Selectin levels were then correlated to patient outcomes in terms of mortality using
Wilcoxon Mann Whitney tests. Signiﬁcance was assigned at
alpha = .05.

Results
Comparison of Inﬂammatory and Hemostatic Biomarker
Levels
Table 1 shows the mean values of each of the individual biomarkers in comparison to normal. The mean value of
D-dimer in PE patients is 6986 ng/mL, MMP-9 is 815 ng/mL,
CRP is 36 ug/mL, PAI-1 is 69 ng/mL, microparticles is
80 nM, P-selectin is 95 ng/mL, TNFa is 98 pg/mL,
alpha-2-antiplasmin is 90%, E-selectin is 65 ng/mL, and
L-selectin is 1468 ng/mL. When compared to the internal
control, NHP, the biomarker that was most magniﬁed in the
PE patient cohort was D-dimer, with a magniﬁcation of 34.6.
After D-dimer the biomarkers that were ampliﬁed in PE patients
were MMP-9 (fold change 16.1), CRP (fold change of 9.0),
PAI-1 (fold change of 3.1), Microparticles (fold change of
2.8 nM), P-selectin (fold change of 2.1), and TNFa (fold
change of 2.0). Alpha-2-antiplasmin, E-selectin, and
L-selectin had lower levels in PE patients when compared to
NHP. Fold change of alpha-2-antiplasmin was 0.9, fold
change of E-selectin was 0.9, and fold change of L-selectin
was 0.8. Figure 1 shows a composite of the individual distribution proﬁles of each of these biomarkers, illustrating the interquartile ranges.

Comparison of Selectin Levels in PE Patients and
Controls
Figure 2 shows the distribution proﬁle of selectin levels in both
PE patients and controls. In PE patients, P-selectin levels were
increased to 95 ng/mL as compared to 40 ng/mL in the control
group. E-selectin levels in PE patients were slightly increased at
65 ng/mL, as compared to control levels of 61 ng/mL.
L-selectin levels in PE patients were reduced at 1468 ng/mL,
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Figure 1. A Composite Representation of the Distribution Proﬁle of Various Biomarkers in PE Patients.

Figure 2. A Comparison on P, E, and L-selectin Levels in PE Patients as Compared to Normal Controls.
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as compared to control levels of 1934 ng/mL. Non-parametric
Wilcoxon Mann Whitney results on the data indicated that
P-selectin levels were signiﬁcantly magniﬁed, with p < .0001.
L-selectin levels were signiﬁcantly decreased, with p < .0001.
E-selectin levels indicated no signiﬁcant change as compared
to normal controls, with p = 0.51.

Correlational Studies Among Hemostatic and
Inﬂammatory Biomarkers
Correlational relationships among P, E, and L-selectin, TNFa,
PAI-1, and D-dimer are performed. Figure 3 shows composite
correlation coefﬁcients among various biomarkers investigated.
P-selectin and E-selectin had a correlation coefﬁcient of 0.43.
P-selectin and PAI-1 demonstrated a correlation coefﬁcient of
0.39. P-selectin and D-dimer had a correlation coefﬁcient of
0.28. Finally, TNFa and L-selectin had a correlation coefﬁcient
of 0.24.
Among each biomarker pair, four pairs of biomarkers were
found to be statistically signiﬁcant. Figure 4 shows the correlation curves for these four pairs of biomarkers. The most
strongly correlated were P and E selectin, with r = .43 (p =
.00001, 95% CI = 0.247to 0.580, n = 100). P-selectin and
PAI-1 exhibited the second strongest correlation with r = .39
(p = .00006, 95% CI = 0.206 to 0.554, n = 98). P-selectin and
D-dimer had the third strongest correlation with r = .28 (p =
.01, CI = .064 to .472, n = 84). The ﬁnal biomarker pair that
was statistically signiﬁcant was L-selectin and TNFa, with r =
.24 (p = .033, 95% CI = .013 to .451, n = 76).

Association of Selectins and All-Cause Mortality
As shown in Table 2, patient outcomes in terms of mortality
were tabulated. Of the 100 patients in whom selectin levels

Figure 3. A composite of the Correlation of Various Biomarkers of
Hemostatic Activation, Inﬂammation, and Selectins in PE Patients
Compared to Normal Controls.
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were studied, 88 were living at the time of analysis and 12
were deceased at that time. Mean levels of P, E, and
L-selectin in living PE patients were compared to those who
were deceased at the time of analysis. Interestingly, the mean
P-selectin levels in the deceased patients was 80 ng/mL,
which was marginally increased compared to the level in
living patients, 75 ng/mL. E-selectin levels in deceased patients
were also slightly elevated at 69 ng/mL as compared to the
mean level in living patients 58 ng/mL. L-selectin levels in
deceased patients had an average of 1046 ng/mL as compared
to the level in survivors, 1391 ng/mL, and this difference was
statistically signiﬁcant, with p = .040. P-selectin and
E-selectin did not exhibit statistical signiﬁcance when related
to all-cause mortality, with p-values of 0.252 for P-selectin
and 0.504 for E-selectin respectively.

Discussion
The pathophysiology of PE is a complex process where the dysregulation of the coagulation process and inﬂammatory activation plays an important role.1,2 The proﬁling of biomarkers of
hemostatic activation and measurement of inﬂammatory mediators provides additional insight into the pathogenesis of PE not
previously evaluated in clinical settings. The biomarkers analyzed were also compared with plasma samples collected
from normal healthy volunteers to examine the changes in the
circulating levels of these analytes. The major ﬁndings in this
study include that P-selectin levels are signiﬁcantly elevated
in PE patients, L-selectin levels are signiﬁcantly reduced, and
that statistically signiﬁcant correlational relationships do exist
between the selectin molecules and other biomarkers of hemostasis and thrombosis. These correlations demonstrate that
adhesion molecules are important markers for the inﬂammatory
state and hematologic dysregulation found in PE.
Our study found a marked increase in D-dimer level, suggesting endogenous formation of thrombin associated with
thromboembolic complication.2 Additionally, microparticles
from the endogenous consumption of thrombogenic membranes of cells were also elevated in the PE cohort as compared
to the reference group.21,22 Such markers of inﬂammation
including MMP-9, a matrix degrading protease, and CRP
were also increased in our PE cohort. The PAI-1 levels which
indicate the increased inﬂammatory process and ﬁbrinolytic
deﬁcit were also elevated in the PE cohort.23,24 TNFa, which
represents a hallmark of tissue factor activation of macrophages
in various inﬂammatory conditions, was also elevated in the PE
cohort.25 Overall, our study demonstrates an upregulation in
hemostatic biomarkers and inﬂammatory cytokines. The PE
cohort showed wide variations which may be related to the difference in the pathophysiologic state and individual predisposition of recruited PE patients. In this study, the patients were
randomly recruited and were not selected on the basis of established criteria. However, upon the recruitment of additional
patients, the analysis of a larger cohort may provide enough
sample size to carry out subgroup analysis. The purpose of
the study was to identify measurable biomarkers to predict
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Figure 4. Correlation Plots of Various Biomarkers Showing Singifcant Relationships in the PE Patient Cohort.

outcomes and the nature of the pathogenesis of the patient population in the PERT program.
Table 2. Selectin Levels and Their Relationship with Mortality
Outcome in PE cohort.
Selectin

Survivor Selectin
Levels (ng/mL)

Non-Survivor Selectin
Levels (ng/mL)

P-value

P-selectin
E-selectin
L-selectin

75 (44-126)
58 (41-84)
1391 (1093-1826)

80 (59-197)
69 (52-74)
1046 (868-1302)

0.252
0.504
0.040

The mortality outcome in terms of survivor and non-survivors was calculated
utilizing Wilcoxon-Mann-Whitney U Tests for the PE cohort.

Since the pathogenesis of PE is multifactorial, the data collected on various biomarkers was subjected to correlation analysis. In this analysis, P-selectin strongly correlated with PAI-1
(r = 0.39), suggesting the role of platelets in regulating PAI-1. It
has been reported previously that platelets secrete antiﬁbrinolytic mediators, such as alpha-2-antiplasmin, however,
in our study the relationship of PAI-1 and P-selectin is suggestive of the role of P-selectin in regulating PAI-1.24,26,27
P-selectin was also the only adhesion molecule which was signiﬁcantly increased in the PE cohort. Interestingly, P-selectin
levels also correlated signiﬁcantly with D-dimer, suggesting
the role of this adhesion molecule in enhancing the level of
thrombin generation and subsequent formation of ﬁbrin
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degradation product, as measured by D-dimer levels.28
L-selectin levels demonstrated a signiﬁcant correlation with
TNFa levels, which is consistent with the activation of white
cells and their subsequent role in upregulating TNFa.15
Overall, proﬁling multiple biomarkers provides a comprehensive evaluation of the complex pathways and systemic molecular and cellular dysregulation that occurs in PE.
The adhesion molecules, namely P-selectin, E-selectin, and
L-selectin, showed variable responses in PE patients.
P-selectin levels were increased in PE patients, L-selectin
levels were lowered, and the E-selectin levels were not signiﬁcantly different from the normal control cohort. The increase in
P-selectin suggests that the activation of platelets plays a prominent role in the thrombogenesis in PE. It is thought that
P-selectin levels are augmented in PE patients due to the platelet
aggregation necessary for initial thrombus formation.10,29
Levels of free L-selectin are predicted to have been diminished
due to consumption of leukocytes within the thrombus itself,
reducing the level that is free to circulate in the patient
plasma. While E-selectin levels have been demonstrated to be
correlated to P-selectin levels, perhaps due to their nature of
sharing a common ligand, PSGL-1, the level of E-selectin
between PE patients and controls did not differ signiﬁcantly.4
Due to known mechanistic roles of D-dimer and PAI-1 in
thrombus formation, the statistically signiﬁcant correlation of
P-selectin to these markers conveys that P-selectin may too
share a responsibility in thrombogenesis.28,30
L-selectin has previously been reported to be upregulated in
states of inﬂammation, and since TNFa is a well documented
marker of inﬂammation, its correlation to this biomarker
further supports this concept..12,26 The correlation of the lowering of circulating L-selectin levels to all-cause mortality is of
particular importance. Since L-selectin is an adhesion molecule,
it is likely that circulating L-selectin is decreased because of its
adhesion to endothelial surfaces where the honing of leukocytes
takes place during thrombo-inﬂammatory processes. It is
thought that because L-selectin is so strongly connected to the
inﬂammatory state, this relationship to mortality derives from
greater levels of inﬂammation in non-survivors as compared
to survivors.12 This paves the path for future management of
PE in the form of greater focus on anti-inﬂammatory therapy
to improve prognostic outcome.

Study Limitations
This study was limited by the inclusion of a small sample size of
100 PE patients, which were recruited in conjunction with the
PERT program. This study, therefore, represents a pilot study
to determine the prognostic signiﬁcance of some of the
markers in PE patients. A larger number of patient inclusion
may provide further validation of the observations noted in
this study. The study was also limited by inclusion of a heterogeneous group of patients, including low, intermediate and high
risk severity PE. Additionally, within the patient population
there was also the presence of other comorbidities, which
were more prevalent than in our controls which could
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potentially skew the data analyzed. Further, this study only utilized select biomarkers which represent different pathogenic
processes. This study can be further augmented by the inclusion
of other biomarkers of inﬂammation and hemostatic activation.
In this study only one baseline sample was collected at the time
of conﬁrmed diagnosis of PE, which represented a 72-hour span
after the onset of PE. Differences in the timing of specimen collection may also have contributed to the observed variations
noted as medical therapies given may impact biomarkers in
addition to the evolving inﬂammatory changes of PE over
time. Despite these limitations, this study has provided valuable
information in the understanding of the pathogenesis of PE and
the interrelationship between the hemostatic and inﬂammatory
processes in mediating the complex pathophysiology of PE.
The information generated may be useful in the risk stratiﬁcation and overall management of PE patients.

Conclusion
In this pilot study, P, E and L-selectins are signiﬁcantly correlated with some of the known biomarkers of hemostatic activation and inﬂammation in the setting of PE. Levels of L-selectin
were also found to be inversely associated with mortality outcomes in PE patients. The observed elevation of other biomarkers is suggestive of the interrelationship of selectins and these
mediators in the overall pathophysiology of PE. Proﬁling of
these biomarkers in an integrative manner and inclusion of
other adhesion molecules may provide additional insight into
the molecular pathogenesis of PE-associated vascular dysfunctions and hemodynamic changes. This pilot study warrants
further investigation in a larger cohort of PE patients to validate
the prognostic value of these biomarkers for the optimal management of PE.
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